Keywords: xenova, anticancer, drug, enter, ph, iii, clinical

Xenova's anticancer drug to enter Ph III clinical trials

Article | 07 March 2000

Print This

Xenova Group of the UK says it is to move its anticancer compound XR9576into pivotal trials in combination with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in